Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines

Vaccine

Volumn 30, Issue 17, 2012, Pages 2715-2727

  Hess, Ralf D ^a   Weber, Friedemann ^b,c   Watson, Keith ^a   Schmitt, Siegfried ^a  

^a PAREXEL INTERNATIONAL   (United States)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Cell bank characterisation; Cell substrates; Live attenuated virus vaccines; Oncogenicity; Regulations; Tumourigenicity

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; DIPLOID CELL VACCINE; LIVE VACCINE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; ROTAVIRUS VACCINE; VACCINE; VIRUS VACCINE;

ADENOVIRUS; ANEUPLOIDY; BIOSAFETY; CARCINOGENICITY; CELL CULTURE; CELL STRAIN BHK; CELL STRAIN HEK293; CHO CELL; CYTOKINE PRODUCTION; DIPLOIDY; EXPRESSION VECTOR; FIBROBLAST; HEMADSORPTION; HUMAN; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOSTIMULATION; MUMPS VIRUS; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RUBELLA VIRUS; SIMIAN VIRUS 40; SUPERNATANT; TRANSMISSION ELECTRON MICROSCOPY; VACCINE PRODUCTION; VERO CELL; VIRUS CHARACTERIZATION; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; CELL CULTURE TECHNIQUES; CELL LINE; HUMANS; VACCINATION; VACCINES;

EID: 84858700318     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.02.015     Document Type: Review

References (114)

1. Pandemic influenza vaccines: current status, pandemic (H1N1) 2009 briefing note 11; 24 September 2009. http://www.who.int/csr/disease/swineflu/notes/pandemic_influenza_vaccines_20090924/en/index.html.
2. Hess R.D., Ghosh P. Vaccines: preventive and therapeutic vaccines and adjuvants on the rise. J Clin Studies 2009, 40-43.
3. Patriarca P.A. Use of cell lines for the production of influenza virus vaccines: an appraisal of technical, manufacturing, and regulatory considerations initiative for vaccine research 10 April 2007, World Health Organization, Geneva, Switzerland. http://www.who.int/vaccine_research/diseases/influenza/WHO_Flu_Cell_Substrate_Version3.pdf.
4. Robertson J.S. Clinical influenza virus and the embryonated hen's egg. Rev Med Virol 1993, 3:97-106.
5. EMA/CHMP/BWP/68803/2010 Committee for human medicinal products (CHMP) guideline on quality aspects on the isolation of candidate influenza vaccine viruses in cell culture, draft 14 April 2010, , http://tinyurl.com/6yj3c5j. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/06/WC500091535.pdf.
6. WHO/DRAFT/4 May 2010 Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks. Proposed replacement of TRS 878, Annex 1 18-22 October 2010, Expert Committee on Biological Standardization, Geneva. http://www.who.int/biologicals/publications/trs/areas/vaccines/cells/Cell_Substrates_for_public_consultation_HK_4_May2.pdf.
7. USP-NF <1235> Vaccines for human use-general considerations.
8. USP-NF <1237> Virology test methods.
9. USP-NF <1050> Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin.
10. CBER 2001: United States of America, Food and Drug Administration Center for Biologics Evaluation and Research, Vaccines and related Biologicals Products Advisory Committee, Meeting Wednesday; May 16, 2001. http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3750t1_01.pdf.
11. Farson D., Tao L., Ko D., Li Q., Brignetti D., Segawa K., et al. Development of novel E1-complementary cells for adenoviral production free of replication-competent adenovirus. Mol Ther 2006, 14(2):305-311.
12. Guidance for industry: characterization and qualification of cell substrates and other biological starting materials used in the production of viral vaccines for the prevention and treatment of infectious diseases. Draft Guidance US CBER; September 2006. , . http://tinyurl.com/6h6xssk.
13. Guidance for industry: characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications; February 2010. http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm202439.pdf.
14. CBER (Center for Biologics Evaluation and Research), U.S.Food and Drug Administration Points to consider in the characterization of cell lines used to produce biologicals 1993.
15. EudraLex-Volume 4, Good manufacturing practice (GMP) guidelines. http://ec.europa.eu/health/documents/eudralex/vol-4/index_en.htm.
16. European Pharmacopoeia (EP) 01/2009:0153 Vaccines for human use.
17. European Pharmacopoeia (EP) 5.1.7. Viral safety.
18. European Pharmacopoeia (EP) 5.2.2. Chicken flocks free from specific pathogens for the production and quality control of vaccines.
19. European Pharmacopoeia (EP) 5.2.3. Cell substrate for the production of vaccines for human use.
20. European Pharmacopoeia (EP) 2.6.16. Tests for extraneous agents in viral vaccines for human use.
21. EMEA/CPMP/BWP/2289/01. Points to consider on the development of live attenuated influenza vaccines.
22. CPMP/1100/02. Note for guidance for the development of vaccinia virus based vaccines against smallpox.
23. EMEA/CHMP/BWP/398498/2005-corr. Guideline on virus safety evaluation of biotechnological investigational medicinal products.
24. EMEA/CHMP/VWP/141697/2009. Draft guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines.
25. ICH Harmonised Tripartite Guideline: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin Q5A(R1). http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html.
26. ICH Harmonised Tripartite Guideline: quality of biotechnological products: analysis of the expression construct in cells used for production of r-DNA derived protein products, Guideline Q5B. Current Step 4 version; 30 November 1995. http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html.
27. ICH Harmonised Tripartite Guideline: derivation and characterization of cell substrates used for production of biotechnological/biological products Q5D. Current Step 4 version; 16 July 1997. http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html.
28. World Health Organization Requirements for the use of animal cells as in vitro substrates for the production of biologicals 1998, WHO Technical Report Series, No. 878. http://www.who.int/biologicals/publications/trs/areas/vaccines/cells/WHO_TRS_878_A1Animalcells.pdf.
29. Knezevic I., Stacey G., Petricciani J. WHO Study Group on cell substrates for production of biologicals, Geneva, Switzerland, 11-12 June 2007. Biologicals 2008, 36:203-211.
30. Evaluation of cell substrates for the production of biologics. Revision of WHO recommendations. Report of the WHO Study Group on cell substrates for the production of biological 22-23 April 2009, WHO, Bethesda, USA.
31. Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks. Proposed replacement of TRS 878, Annex I. http://www.who.int/biologicals/Cell_Substrates_clean_version_18_April.pdf.
32. WHO/BS/10.2132 Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks. Proposed replacement of TRS 878, Annex I 18-22 October 2010, Expert Committee on Biological Standardization, Geneva, http://www.who.int/biologicals/BS2132_CS_Recommendations_CLEAN_19_July_2010.pdf, http://tinyurl.com/6a982gm.
33. Technical report series: vaccines, . http://tinyurl.com/6argpwl.
34. EUDRALEX, Volume 4EU guidelines for good manufacturing practice for medicinal products for human and veterinary use Draft Annex 2. http://ec.europa.eu/health/documents/latest_news/gmp_annex2_03-2010.pdf.
35. Hartung T., Balls M., Bardouille C., Blanck O., Coecke S., Gstraunthaler G., et al. Good cell culture practice ECVAM good cell culture practice task force report 1. ATLA 2002, 30:407-414.
36. Coecke S., Balls M., Bowe G., Davis J., Gstraunthaler G., Hartung T., et al. Guidance on good cell culture practice, a report of the second ECVAM task force on good cell culture practice. ATLA 2005, 33:261-287.
37. Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks. WHO, Draft; 8 July 2009. http://2009.ncnv.org/who.html.
38. Lewis A.M., Brown E.L., Duncan P.A. Approaches to the release of a master cell bank of PER.C6 cells; a novel cell substrate for the manufacture of human vaccines. Dev Biol 2006, 123:165-176.
39. Ledwith B.J., Lanning C.L., Gumprecht L.A., Anderson C.A., Coleman J.B., Gatto N.T., et al. Tumourigenicity assessments of PER.C6 cells and of an Ad5-vectored HIV-1 vaccine produced on this continuous cell line. Dev Biol 2006, 123:251-263.
40. Vaccines and related biological products advisory committee, meeting, May 16, 2001, on designer cells as substrates for the manufacture of viral vaccines. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3750b1_01.htm.
41. Braun S.W., Mehtali M. The avian EB66(R) cell line, application to vaccines, and therapeutic protein production. PDA J Pharm Sci Technol 2010, 64(5):419-425.
42. Jordan I., Vos A., Beilfuss S., Neubert A., Breul S., Sandig V. An avian cell line designed for production of highly attenuated viruses. Vaccine 2009, 27(5):748-756.
43. Lohr V., Rath A., Genzel Y., Jordan I., Sandig V., Reichl U. New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation. Vaccine 2009, 6(27):4975-4982.
44. US Patent Application, No. 2010/0021499 A1, . http://ip.com/patapp/US20100021499.
45. Graham F.L., Smiley J., Russell W.C., Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977, 36:59-74.
46. Kay M.A., Glorioso J.C., Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001, 7:33-40.
47. Vile R., Ando D., Kirn D. The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider. Cancer Gene Ther 2002, 9:1062-1067.
48. Priddy F.H., Brown D., Kublin J., Monahan K., Wright D.P., Lalezari J., et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008, 46(11):1769-1781.
49. Lewis A.M. A defined-risks approach to the regulatory assessment of the use of neoplastic cells as substrates for viral vaccine manufacturer. Dev Biol 2001, 106:513-535.
50. Hickling J., D'Hondt E. Review of production technologies for influenza virus vaccines, and their suitability for deployment in developing countries for influenza pandemic preparedness December 20, 2006, World Health Organization Initiative for Vaccine Research, Geneva, Switzerland. http://www.who.int/vaccine_research/diseases/influenza/Flu_vacc_manuf_tech_report.pdf.
51. Bukreyev A., Skiadopoulos M.H., McAuliffe J., Murphy B.R., Collins P.L., Schmidt A.C. More antibody with less antigen: can immunogenicity of attenuated live virus vaccines be improved?. Proc Natl Acad Sci U S A 2002, 99(2):16987-16991.
52. Hess R.D., Brandner G. p53 in normal and neoplastic tissue: analysis and function. EI J Pathol Histol 1996, 961-1007. [review].
53. Levine A.J. The common mechanisms of transformation by the small DNA tumour viruses: the inactivation of tumour suppressor gene products: p53. Virology 2009, 384:285-293.
54. Sieber T., Dobner T. Adenovirus type 5 early region 1B 156R protein promotes cell transformation independently of repression of p53-stimulated transcription. J Virol 2007, 81:95-105.
55. Barrett A.D.T., Stanberry L.R. Vaccines for biodefense and emerging and neglected diseases 2009, Academic Press, UK. Barrett, Stanberry (Eds.).
56. Subbarao K., Chen H., Swayne D., Mingay L., Fodor E., Brownlee G., et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 2003, 305:192-200.
57. Audsley J.M., Tannock G.A. Cell-based influenza vaccines: progress to date. Drugs 2008, 68:1483-1491.
58. Chen Z., Wang W., Zhou H., Suguitan A.L., Shambaugh C., Kim L., et al. Generation of live attenuated novel influenza A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. J Virol 2009, [28 October, Epub ahead of print].
59. Samuel C.E. Antiviral actions of interferons. Clin Microbiol Rev 2001, 14:778-809.
60. Krishnamurthy S., Takimoto T., Scroggs R.A., Portner A. Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol 2006, 80:5145-5155.
61. Stojdl D.F., Lichty B., Knowles S., Marius R., Atkins H., Sonenberg N., et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000, 6:821-825.
62. Battcock S.M., Collier T.W., Zu D., Hirasawa K. Negative regulation of the alpha interferon-induced antiviral response by the Ras/Raf/MEK pathway. J Virol 2006, 80:4422-4430.
63. Mundschau L.J., Faller D.V. Oncogenic ras induces an inhibitor of double-stranded RNA-dependent eukaryotic initiation factor 2 alpha-kinase activation. J Biol Chem 1992, 267:23092-23098.
64. Strong J.E., Coffey M.C., Tang D., Sabinin P., Lee P.W. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. J EMBO 1998, 17:3351-3362.
65. Balachandran S., Barber G.N. Defective translational control facilitates vesicularstomatitis virus oncolysis. Cancer Cell 2004, 5:51-65.
66. Coffey M.C., Strong J.E., Forsyth P.A., Lee P.W. Reovirus therapy of tumors with activated Ras pathway. Science 1998, 282:1332-1334.
67. Montagnon B.J. Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line. Dev Biol Stand 1989, 70:27-47.
68. Barrett P.N., Mundt W., Kistner O., Howard M.K. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines 2009, 8:607-618.
69. Desmyter J., Melnick J.L., Rawls W.E. Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero). J Virol 1968, 2:955-961.
70. Emeny J.M., Morgan M.J. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. J Gen Virol 1979, 43:247-252.
71. Diaz M.O., Ziemin S., Le Beau M.M., Pitha P., Smith S.D., Chilcote R.R., et al. Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines. Proc Natl Acad Sci U S A 1988, 85:5259-5263.
72. Mosca J.D., Pitha P.M. Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis. Mol Cell Biol 1986, 6:2279-2283.
73. Habjan M., Penski N., Spiegel M., Weber F. T7 RNA polymerase-dependent and -independent systems for cDNA-based rescue of Rift Valley fever virus. J Gen Virol 2008, 89:2157-2166.
74. Sumpter R., Loo Y.M., Foy E., Li K., Yoneyama M., Fujita T., et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 2005, 79:2689-2699.
75. Young D.F., Andrejeva L., Livingstone A., Goodbourn S., Lamb R.A., Collins P.L., et al. Virus replication in engineered human cells that do not respond to interferons. J Virol 2003, 77:2174-2181.
76. Randall R.E., Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008, 89:1-47.
77. Versteeg G.A., Garcia-Sastre A. Viral tricks to grid-lock the type I interferon system. Curr Opin Microbiol 2010, 13:508-516.
78. Weber F., Haller O. Viral suppression of the interferon system. Biochimie 2007, 89(6-7):836-842.
79. Shingai M., Ebihara T., Begum N.A., Kato A., Honma T., Matsumoto K., et al. Differential type I IFN-inducing abilities of wild-type versus vaccine strains of measles virus. J Immunol 2007, 179:6123-6133.
80. Young D.F., Galiano M.C., Lemon K., Chen H.Y., Andrejeva J., Duprex W.P., et al. Mumps virus Enders strain is sensitive to interferon (IFN) despite encoding a functional IFN antagonist. J Gen Virol 2009, 90:2731-2738.
81. Mayr A., Hochstein-Mintzel V., Stickl H. Abstammung, Eigenschaften und Verwendung des attenuierten vaccinia-stammes MVA. Infection 1975, 3:6-14.
82. Meyer H., Sutter G., Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 1991, 72:1031-1038.
83. Antoine G., Scheiflinger F., Dorner F., Falkner F.G. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 1998, 244:365-396.
84. Garber D.A., O'Mara L.A., Zhao J., Gangadhara S., An I., Feinberg M.B. Expanding the repertoire of modified vaccinia Ankara-based vaccine vectors via genetic complementation strategies. PLoS One 2009, 4(5):e5445. 10.1371/journal.pone.0005445.
85. Carroll M.W., Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 1997, 238:198-211.
86. Sander C.R., Pathan A.A., Beveridge N.E.R., Poulton I., Minassian A., Alder N., et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med 2009, 179:724-733.
87. Kennedy J.S., Greenberg R.N. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines 2009, 8(1):13-24.
88. Butel J.S. Simian virus 40, poliovirus vaccines, and human cancer: research progress versus media and public interests. Bull World Health Organ 2000, 78:195-198.
89. Hanagarth H.G., Obert M., Hess R., Haessler C., Braun D.G., Brandner G. The cell binding carboxyterminal undecapeptide of SV40 tumour antigen provides protective cell-dependent immunity. Vaccine 1994, 12:1197-1202.
90. Obert M., Pleuger H., Hanagth H.G., SchulteMönting J., Wiesmüller K.H., Braun D., et al. Protection of mice against SV40 tumours by Pam3Cys, MTP-PE and Pam3Cys conjugated with the SV40T antigen derived peptide K(698)-T(708). Vaccine 1998, 16:161-169.
91. Hess R.D., Brandner G. DNA-damage-inducible p53 activity in SV40-transformed cells. Oncogene 1997, 15:2501-2504.
92. Martini F., Corallini A., Balatti V., Sabbioni S., Pancaldi C., Tognon M. Simian virus 40 in humans. Infect Agent Cancer 2007, 2:13. 10.1186/1750-9378-2-13.
93. Masters J.R., Twentyman W., Arlett P., Daley C., Davis R., Doyle J., et al. UKCCCR guidelines for the use of cell lines in cancer research. Br J Cancer 2000, 82(9):1495-1499.
94. Masters J.R. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci U S A 2002, 98:8012-8017.
95. US FDA, CBER, Vaccines and related biological products advisory committee meeting, Wednesday, 16 May 2001. http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3750t1_01.pdf.
96. WHO/DRAFT/4 May 2010 Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks Proposed replacement of TRS 878, Annex 1, . http://www.who.int/biologicals/publications/trs/areas/vaccines/cells/Cell_Substrates_for_public_consultation_HK_4_May2.pdf.
97. Shen C., Gu M., Song C., Miao L., Hu L., Liang D., et al. The tumourigenicity diversification in human embryonic kidney 293 cell line cultured in vitro. Biologicals 2008, 36(4):263-268.
98. Medema J.K., Meijer J., Kersten A.J., Horton R. Safety assessment of Madin Darby canine kidney cells as vaccine substrate. Dev Biol 2006, 123:243-250.
99. Coleman W.B., Tsongalis G.J. Molecular mechanisms of human carcinogenesis. EXS 2006, (96):321-349.
100. Chai H., Brown R.E. Field effect in cancer-an update. Ann Clin Lab Sci 2009, 39:331-337.
101. Oxford G., Theodorescu D. Ras superfamily monomeric G proteins in carcinoma cell motility. Cancer Lett 2003, 189(2):117-128.
102. Manohar M., Orrison B., Peden K., Lewis A.M. Assessing the tumorigenic phenotype of Vero cells in adult and newborn mice. Biologicals 2008, 36(1):65-72.
103. McPherson I., Montagnier I. Agar suspension culture for the selective assay of cells transformed by polyoma virus. Virology 1964, 23:291-294.
104. Petricciani J.C., Levenbook I., Locke R. Human muscle: a model for the study of human neoplasia. Invest New Drugs 1983, 1:297-302.
105. Masters J.R. HeLa cells 50 years on: the good, the bad and the ugly. Nat Rev Cancer 2002, 2:315-319.
106. Petricciani J.C., Regan P.J. Risk of neoplastic transformation from cellular DNA: calculations using the oncogene model. Dev Biol Stand 1987, 68:43-49.
107. CPMP/BWP/1143/00 Position statement on the use of tumourigenic cells of human origin for the production of biological and biotechnological medicinal products.
108. Khan A.S. Cell substrates for viral vaccines: a regulatory update. The International Association for Biologicals and the Fraunhofer USA Center for Molecular Biotechnology Congress: new cells for new vaccines IV - changing the vaccine landscape: recombinant systems 2009, http://2009.ncnv.org/.
109. Rogers Y.H., Venter J.C. Genomics: massively parallel sequencing. Nature 15 September 2005, 437:326-327. [published online 14 September 2005]. 10.1038/437326a.
110. Onions D., Kolman J. Massively parallel sequencing, a new method for detecting adventitious agents. Biologicals 2010, 38(3):377-380. [24 March, Epub ahead of print].
111. Baylis S.A., Finsterbusch T., Bannert N., Blümel J., Mankertz A. Analysis of porcine circovirus type 1 detected in Rotarix vaccine. Vaccine 2011, 29(4):690-697. [18 November, Epub ahead of print].
112. Stacey G.N., Masters J.R. Cryopreservation and banking of mammalian cell lines. Nat Protoc 2008, 12:1981-1989.
113. Khan A.S., Hughes P., Wiebe M. Introduction to workshop: adventitious viruses in biologics-detection and mitigation strategies. PDA J Pharm Sci Technol 2011, 65:544-546.
114. Milstien J., Dellepiane N., Lambert S., Belgharbi L., Rolls C., Knezevic I., et al. Vaccine quality-can a single standard be defined?. Vaccine 2002, 1000-1003.